Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
92 hedge funds and large institutions have $215M invested in Concert Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 13 closing their positions.
41% more call options, than puts
Call options by funds: $3.45M | Put options by funds: $2.44M
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
3% less capital invested
Capital invested by funds: $222M → $215M (-$7.73M)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 93 → 92 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$13.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$4.88M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.46M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.76M |
| 5 |
Barclays
London,
United Kingdom
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$8.79M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.99M |
| 3 |
Millennium Management
New York
|
-$2.72M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.79M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.46M |
CNCE Hedge Fund Activity: Q1 2019 in Review
92 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2019, worth a combined $215M — down 3.5% from $222M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CNCE and 12 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 34 added.
The largest buyer was RTW Investments, adding an estimated $13.3M. The largest seller was First Manhattan, cutting an estimated $8.79M.
- 92 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2019, down from 93 in Q4 2018.
- Funds reported $215M of Concert Pharmaceuticals, Inc. stock for Q1 2019, down 3.5% quarter-over-quarter.
- 12 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2019 and 13 closed out, a net change of -1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2019 was RTW Investments, an estimated $13.3M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2019 was First Manhattan, an estimated $8.79M sold.
Based on aggregated 13F filings for Q1 2019.